Market capitalization | $19.37m |
Enterprise Value | $24.09m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 10.85 |
P/S ratio (TTM) P/S ratio | 8.73 |
P/B ratio (TTM) P/B ratio | negative |
Sales growth (TTM) Sales growth | -40.23% |
Turnover (TTM) Turnover | $2.22m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
3 Analysts have issued a Renalytix Plc - ADR forecast:
3 Analysts have issued a Renalytix Plc - ADR forecast:
Mar '24 |
+/-
%
|
||
Net profit | -7.74 -7.74 |
36%
36%
|
|
Depreciation and amortization | 0.07 0.07 |
46%
46%
|
|
Share compensation | 0.38 0.38 |
51%
51%
|
|
Operating cash flow | -4.86 -4.86 |
52%
52%
|
|
Investments | - - |
-
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -4.87 -4.87 |
52%
52%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in Penarth, the United Kingdom.
Head office | United Kingdom |
CEO | James McCullough |
Founded | 2018 |
Website | www.renalytixai.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.